MolMed S.p.A - MLM

MolMed S.p.A., a medical biotechnology company, focuses on the research, development, and clinical validation of anticancer therapies. The company’s pipeline include Zalmoxis (TK), a cell based therapy product, which is in Phase III clinical trial that is used for the treatment of hematological malignancies. Its products pipeline also comprise NGR-hTNF, a biological drug for the treatment of solid tumors, which displays antitumor activity through its specific binding to blood vessels feeding the tumor mass. In addition, the company’s preclinical development product includes CAR-CD44v6, an immuno-gene therapy project for the treatment of various hematological malignancies and epithelial tumors. Further, it conducts cell and gene therapy projects in collaboration with third parties, such as the cGMP production of clinical-grade viral vectors; and manufacturing of patient-specific genetically engineered cells. MolMed S.p.A. was founded in 1996 and is headquartered in Milan, Italy.